Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hospital Avoidance Strategies for ABSSSI
NCT03372941Phase 4Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Washington University School of Medicine. Started Mar 2019; status: terminated.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03372941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372941.